% | $
Quotes you view appear here for quick access.

Keryx Biopharmaceuticals Inc. Message Board

  • daytrade76125 daytrade76125 Jun 13, 2011 12:52 PM Flag

    Is this stock broken technically?

    I notice every day it opens up, but falls to lows late in the day. That can't be a good sign. Any insights from any of you chart experts? Will this continue to tank?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • It would be. But only if it was the only (or any other indication that it was falling due to it's own failings) one in the market dropping.

      Obviously this isn't so. The entire market is dropping, so there's 2 things you should do. Hold, or Buy.

    • Another close near the low of the day. I bought in at 4.75 because each time it fell to around that level recently, it popped back up to 5 dollars or higher. But it feels different this time. It's below the stock offering level now and seems to be in tank mode. I'm losing a lot of money here and I wonder how much more this can drop. I would hope it would run up as phase III results are due out later this year, but it's going in the wrong direction. Too frustrating.

    • Anyone following KERX knows what's happening. I'm suprised we have someone on this board who doesn't. Here's the skinny:
      Nothing significant is going to happen to this stock until the end of this year/early next year. Until then, MM will be playing with it, bobbing it up and down taking small profits.
      That's about it. My suggestion? HOLD what you have and BUY on the dips.

      • 2 Replies to advisor321
      • Good advice from an intelligent, sensible person - who can actually spell words correctly. Thanks

      • Well said advisor123. Perifosine data is "expected" in Q4 2011. Since this is an "event driven study" patients need to progress on both arms of the trial. Based upon the data from the phase 2 program, KERX management is forecasting a readout of this trial in Q4. If the data is delayed, it may suggest an even larger than expected benefit in the investigational arm (perifosine arm) of the trial.

        Other major catalysts will need to wait until 2H 2012. Perifosine's other exciting phase 3 program is expected to generate results in the second half of next year. Also, Zerenex (their differentiated phosphate binder for hyperphosphatemia, or elevated phosphate levels) will have their safety portion of their trial readout in Q3'12 (remember, the efficacy data is already out and POSITIVE). Company plans to file Perifosine in colon and Zerenex by the end of 2012.

        With all of this in mind, the stock is going to drift without any major news until October. Strong hands should hold on. A major event for the company is not far away. If the metastatic colon data is positive, the stock is worth at least $15 based on comparable companies with similar oncology products in major indications (colon cancer is the third most common non-skin cancer in both men and women)

5.44+0.18(+3.42%)Apr 29 4:00 PMEDT